Table 1 Tuberculosis (TB) research priorities identified by researchers, funding received in 2014 and Global Plan funding targets for 2014
From: Investments in tuberculosis research – what are the gaps?
2014 Global Funding ($m) | Priority areas identified by researchersc | ||
|---|---|---|---|
Targeta | Actual spendingb (% of target) | ||
Drugs | 740 | 243.3 (33) | Develop drugs (for drug-susceptible and drug-resistant TB) with higher potency, lower toxicity and shorter duration of treatment; new prophylactic regimens; host direct therapies |
Basic science | 420 | 150.1 (36) | Identify and validate biomarkers for monitoring decease activity, cure, relapse and of immune protection |
Vaccines | 380 | 111.3 (29) | Develop safe and effective vaccines (for adults and HIV-infected patients); understand variability in effectiveness |
Diagnostics | 340 | 65.4 (19) | Improve performance of existing tests; develop new point of care tests (for all forms, including latent and drug-resistant TB) that are cheap, rapid and sensitive |
Operational research | 80 | 52.8 (66) | Assess strategies to optimize implementation of new tools; to improve health worker performance, private provider engagement and integration of TB services |